Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

Byoung Chul Cho, W. Marston Linehan, D. Ross Camidge, V. Velcheti, Benjamin Solomon, Sheng Lu, K.H. Lee, S.W. Kim, Steven Kao, R. Diadziuskzko, Muhammad Shaalan Beg, Misako Nagasaka, Enriqueta Felip, Benjamin Besse, Christoph Springfeld, Sanjay Popat, Jennifer Moriatis Wolf, D. Trone, S. Stopatschinskaja, Alexander Drilon